The role of the Epstein-Barr virus-encoded BARF1 gene expressed in human gastric epithelial cells

Shuying Li¹ , Fang Zhang¹ , Ji Li¹ , Xuya Hu¹ , Wei Zhao¹ , Ke Zhang¹ , Jintao Li²

¹North China University of Science and Technology (Hebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research on Chronic Diseases), Hebei Province, P.R. China

²College of Life Science and Bioengineering, Beijing University of Technology, Beijing, P.R. China

Cite this article as: Li S, Zhang F, Li J, et al. The role of the Epstein-Barr virus-encoded BARF1 gene expressed in human gastric epithelial cells. *Turk J Gastroenterol* 2020; 31(11): 775-81.

ABSTRACT

Background/Aims: The study aimed to explore the effects of Epstein-Barr virus—encoded BARF1 in human gastric epithelial cells (GES-1).

Materials and Methods: A eukaryotic expression vector carrying BARF1 gene (pcDNA3.1-BARF1) was constructed. The pcDNA3.1-BARF1 was transfected into GES-1 cells, and they were selected by G418. The GES-1 cells lines that expressed BARF1 (GES-1-BARF1) were obtained. The cycle of GES-1-pcDNA3.1 cells (GES-1 cells transfected with empty vector), GES-1-BARF1 cells (GES-1 cells transfected with BARF1), and TPA-GES-1-BARF1 (GES-1-BARF1 cells stimulated by 12-O-tetradecanoylphorbol-13-acetate (TPA)) were analyzed by flow cytometry. Colony formation in soft agar and tumorigenicity of the transfected cells in mice with severe combined immunodeficiency (SCID) were also observed.

Results: The morphology of GES-1-BARF1 cells were changed from the original shuttle to round, the adhesion between the cells and bottle wall was weakened, and the cells showed overlapping growth. The proliferation rate of GES-1-BARF1 and TPA-GES-1-BARF1 cells were faster than GES-1 and GES-1-pcDNA3.1 cells; the S phase was significantly prolonged for GES-1-BARF1 and TPA-GES-1-BARF1. GES-1-BARF1 and TPA-GES-1-BARF1 cells formed colonies in soft agar, with a cloning rate of 24.2% (58/240) and 40.0% (96/240), respectively; GES-1 and GES-1-pcDNA3.1 cells did not form colonies in soft agar. Tumors were formed in mice with SCID after injecting TPA-GES-1-BARF1 cell groups. Tumor formation did not occur in mice with SCID after injecting GES-1 and GES-1-pcDNA3.1 cell groups, but nodules were formed in the mice with SCID after injecting GES-1-BARF1 cell groups.

Conclusion: GES-1-BARF1 cells malignant transformation was induced by transfected BARF1 gene and TPA stimulation. This result indicated that tumor formation not only require oncogenes, but also the stimulation of cancer-promoting substance.

Keywords: Gastric cancer, transfection, oncogene

INTRODUCTION

Gastric cancer is the second most common malignant neoplasm causing death worldwide (1). Its occurrence and development involved a variety of factors such as *Helicobacter pylori* infection (2), smoking (3–5), alcohol drinking (3, 6), and dietary factors (5–7). Despite extensive investigations for related factors, the etiology of gastric cancer (GC) has not yet been established.

In 1990, Burke et al. (8) first reported a case of Epstein-Barr virus (EBV)-positive gastric carcinoma. EBV is a common human tumor virus and was shown to be associated with many human diseases such as nasopharyngeal carcinoma (NPC), lymphomas, Burkitt lymphoma, and Hodgkin lymphoma (9, 10). Approximately 10% of GCs worldwide are caused by EBV infection (11–13).

BARF1 gene has been recognized in recent years as a new oncogene encoded by EBV. BARF1 protein expression

can be detected in approximately 90% of EBV-related GC tissues (14, 15). It can promote epithelial cell immortalization and transformation functions (16–19), and it is expressed in EBV-positive NPC and GC tissues during latency and in parallel with the more widely studied protein LMP1 (20, 21). Particularly in EBV-positive GC, BARF1 is expressed in the absence of LMP1, and it possibly plays an important role as an EBV oncogene in the occurrence and development of EBV-related GC (15, 22, 23). Therefore, in this study, the role of BARF1 gene in malignant transformation of human gastric epithelial cells was investigated by establishing GES-1/BARF1 cells.

MATERIALS AND METHODS

Cell Lines

The marmoset B-lymphoblastoid cell line (B95-8) that is infected with EBV, it is as a source of BARF1; Gastric epithelial cells (GES-1). The GES-1 cell lines were cultivated

Corresponding Author: Shuying Li, lsy5001@sina.com; Ke Zhang, 877567295@qq.com; Jintao Li, 511046476@qq.com

Received: November 24, 2018 Accepted: December 7, 2019

© Copyright 2020 by The Turkish Society of Gastroenterology · Available online at turkjgastroenterol.org

DOI: 10.5152/tjg.2020.18827

Table 1. The primers used in this study.

Primer	Sequences (5'-3')	Position	Amplicon size (bp)
BARF1#1	CCGGAATTCGCCACCATGGCCAGGTTTCATCGCTC	165504-165522	666
BARF1#2	TGCTCTAGATTATTGCGACAAGTATCCAG	166150-166169	
BARF1#3	CCAGGTTTCATCGCTCAGCTC	165508-165527	524
BARF1#4	CATAACACCGCCATTGCCG	166012-166031	

Note: Primers 1 and 2 for the purpose of gene sequences, and primers 3 and 4 for the detection.

bp: base pair.

in Dulbecco's modified Eagle's medium, and the B95-8 cells were cultivated using RPMI 1640 (Solarbio Corporation, Beijing, China), supplemented with 10% fetal bovine serum and antibiotics (penicillin and streptomycin, the concentration of each antibiotic was 100 U/mL) under standard conditions. Cells were maintained as a subconfluent monolayer at 37°C in a humidified atmosphere of 5% carbon dioxide (CO₂)/95% air. Exponentially proliferating cells were harvested with 0.25% trypsin and 0.02% ethylenediaminetetraacetic acid, resuspended in fresh medium, and seeded in new flasks. The cells (2×10⁶) were collected and washed with phosphate-buffered saline (PBS). The cells were then separated into two cryotubes and were immediately frozen in liquid nitrogen or stored at -70°C until further use.

Mice with SCID

SCID were used for the study (4-6 weeks of age). They were fed under specific pathogen-free conditions.

Primer Design and Synthesis

BARF1 primers were designed according to GenBank-provided BARF1 gene sequences, and restriction sites were added at both ends of the primers (Table 1).

The Eukaryotic Vector Construction and Transfection of GES-1 Cells and Cloning

RNA was extracted from B95-8 cells, and BARF1 gene was amplified by reverse transcription polymerase chain reaction (RT-PCR). The polymerase chain reaction (PCR) products of BARF1 were cloned into the pUM-T vector and transformed into *E. coli* DH5α. The positive clones were screened. The plasmids were extracted from the selected clones, which were digested with EcoRI and XbaI. The pcDNA3.1 eukaryotic vectors were digested with EcoRI and XbaI. BARF1 and pcDNA3.1 were cut from 1.0% agarose gel, and isolated, purified using a Qiaquick Gel Extraction kit according to the manufacturer's protocol, respectively. Then, pcDNA3.1 and BARF1 were ligat-

ed, which were transfected into *E. coli* DH5α; the positive clones were identified; and the plasmids were extracted.

The eukaryotic vector pcDNA3.1-BARF1 was transfected into the human gastric epithelial cell line GES-1 by Lipofectamine2000 (according to the kit instructions). The cells were digested 3 days after transfection and inoculated into a 48-well plate with 200 cells per well. Then, resistant clones were screened with a culture medium containing 300 µg/mL G418.

BARF1 Gene Expression in Transfected Cells

The cell RNA was extracted from GES-1-BARF1 resistant clones, and BARF1 was amplified by reverse transcriptase PCR (using primer 3 and 4 sets, products 524 base pair [bp], as shown in Table 1).

Cell Counting Kit-8 Assay

During the logarithmic growth phase, 200 µL of cells (cell count of approximately 3×10³ cells/mL) were added into every well of 96-well plates (four wells for each cell group). The cell growth was detected using the method of the cell counting kit-8 (CCK-8, according to the kit instructions), using spectrophotometry to measure the cell concentration after culturing for 24 hours, 48 hours, and 72 hours at 450 nm. The CCK-8 assay was repeated three times. The results were recorded.

The Cell Proliferation Cycle Assay

The logarithmic growth phase cells (cell count of approximately 1×10⁶ cells/mL) were collected after 0.25% trypsin digestion and were washed in cold PBS. Then, 70% precooled ethanol was added, and the cells were fixed at 4°C overnight. The supernatant was removed after 2,000 g centrifugation, and the cells were then washed in 2 mL cold PBS. Then, 300 µL PBS, 2 µL (1:1,000) RNA enzyme water, and 70 µL propidium iodide (PI) dye mixed in the dark for 15 minutes were added. A 300-mesh nylon filter

was used to filter the cells. The cell cycle was analyzed using flow cytometry.

Growth in Soft Agar

Anchorage-independent cell growth was assayed in the upper layer with 0.6 mL complete cell growth medium (containing approximately 4×10^2 cells/mL and 0.33% low-melting-temperature soft-agar) and plated onto prepared in advance 0.6 mL complete cell growth medium containing 0.66% soft agar using a 24-well plate. Each group of cells was inoculated into four wells and labeled. The plate was maintained for 2 weeks at 37°C in a humidified atmosphere of 5% CO₂/95% air. Cell clone formations in soft agar were observed, counted, and photographed with a camera every day. The cells that divided three times, that is, proliferated into eight cells, were defined as a clone, and the clone formation rate was calculated according to the following formula: clone formation rate (%) = number of clones/cells inoculated $\times 100\%$.

Tumorigenicity Experiments

Mice with SCID (4–6 weeks of age) were inoculated with 1 mL cell suspension (cell concentration 2×10^7 living cells/mL) of GES-1, GES-1/pcDNA3.1, GES-1-BARF1, and TPA-GES-1-BARF1 cell groups. Each experimental group consisted of three mice. Tumorigenicity was observed for 1 month after injection into mice with SCID.

RNA was extracted from tumor tissues, and the expression of BARF1 in tumor tissues was then detected by RT-PCR.

Tumor tissues were detected by the hematoxylin and eosin (H&E) staining and immune staining.

Statistical Analysis

The data were expressed as the mean $\pm$ standard deviation, and a two-tailed Student's *t*-test was used for statistical analysis by the Statistical Package for the Social Sciences (IBM Corp.; Armonk, NY, USA) software. Statistical significance was set at $p \leq 0.05$.

RESULTS

Amplification of the Target BARF1 Gene

BARF1 gene was amplified using cDNA of B95-8 RNA as a template, and about 666 bp products for BARF1 were observed and consistent with the expected result.

BARF1 Gene Expression in Transfected Cells

Resistant clones were obtained after 2 weeks of G418 screening, whereas non-transfected cells died. Three re-

Figure 1. The expression of BARF1 gene in transfected cells were identified by RT-PCR.

M1:100 bp ladder. Neg was negative control using sterile double distilled water as a template. B95-8 was positive control of the B95-8 cell cDNA as template. 1 was amplification using GES-1 cell cDNA as template; 2 was amplification using transfected empty vector cell cDNA as template; 3, 4, 5 was amplification using three transfected BARF1 gene cell cDNA as template, respectively. RT-PCR: reverse transcription polymerase chain reaction; bp: base pair.

sistant clones from each transfected cell were selected and amplified. Total RNA was extracted from these positive clone cells (including BARF1 gene-transfected cells and empty vector-transfected cells), and 524 bp amplification products were obtained by reverse transcriptase PCR (Figure 1).

Alteration of BARF1 Affects GES-1 Cell Growth

Each cell group GES-1-BARF1, TPA-GES-1-BARF1, GES-1, TPA-GES-1 and GES-1-pcDNA3.1 was synchronized, and their cell growth activity was evaluated by CCK-8 at 24 hours, 48 hours, and 72 hours (Figure 2). The cell growth activities of GES-1-BARF1 and TPA-GES-1-BARF1 was higher than that of GES-1, TPA-GES-1, and GES-1/pcDNA3.1 cell groups, and these differences became increasingly higher with increasing incubation time.

Alteration of BARF1 Affects the Cell Proliferation Cycle

The cells were fixed and stained using PI fluorescence agent. The cell cycle distribution of GES-1-BARF1 cells, TPA-GES-1-BARF1 cells, GES-1 cells, and GES-1-pcDNA3.1 cells were then detected by flow cytometry (Figure 3). The results of flow cytometry showed that the G1 phase of GES-1-BARF1 cells and TPA-GES-1-BARF1 cells was shortened ($p < 0.05$) and the S phase of these cells was significantly prolonged ($p < 0.05$) compared with that of GES-1-pcDNA3.1 cells and GES-1 cells.

Colony Formation Assay

To determine the activity of these cell groups, the cell growth capacity was examined in 0.33% agar. Approximately 240 living cells from each of the cell groups were

Figure 2. The cell growth activity was valuated at 24 hours, 48 hours, and 72 hours by CCK-8

The CCK-8 assay was done in triplicate and showed standard deviations. The proliferation of null GES-1 cells treated with TPA was shown, and the differences in growth between BARF-1 expressing clones were shown.

Note: Compared GES-1-BARF1 cell group with the control group normal GES-1 (or TPA-GES-1, transfected empty vector GES-1 group), * $p < 0.05$; compared TPA-GES-1-BARF1 with GES-1-BARF1 (or transfected empty vector GES-1, TPA-GES-1, GES-1) group, $\Delta p < 0.05$. CCK-8: cell counting kit-8; TPA: 12-O-tetradecanoylphorbol-13-acetate.

Figure 3. (a) The cell cycle distribution of the normal GES-1 cells groups: G1: 62.53%, G2: 14.75%, S: 22.72%. (b) The cell cycle distribution of transfected empty vector cell groups: G1: 65.66%, G2: 11.28%, S: 23.06%. (c) The cell cycle distribution of transfected BARF1 gene cell groups: G1: 50.40%, G2: 8.65%, S: 40.95%. (d) The cell cycle distribution of TPA stimulation of transfected BARF1 gene cell groups: G1: 44.55 %, G2: 9.49 %, S: 45.96 %. TPA: 12-O-tetradecanoylphorbol-13-acetate.

Figure 4. a, b. (a) The typical clone of transfected BARF1 gene cell groups. (b) The typical clone of TPA stimulation of transfected BARF1 gene cell groups. TPA: 12-O-tetradecanoylphorbol-13-acetate.

seeded in each well of a 24-well plate with 0.33% agar. Colony formation was checked daily until 14 days. On day 5, colony formation was observed under an inverted microscope for transfected with the BARF1 cell groups and their TPA stimulation cell groups, and the number of colony formation for every cell group was counted every 2 days as shown in Table 2. Colony formation of the transfected with BARF1 cell groups and their TPA stimulation cell groups in soft agar under an inverted microscope were presented after culturing for 14 days (Figure 4). The clone formation rate of the transfected with the BARF1 cell groups and their TPA stimulation cell groups was approximately 24.2% (58/240) and 40.0% (96/240) (average of value obtained from four subclones), respectively,

Table 2. The number of clones formed by every cell group.

Groups	Clones/day			
	5	8	11	14
GES-1- BARF1-1	6	15	37	60
GES-1- BARF1-2	2	11	32	57
GES-1- BARF1-3	3	13	35	59
GES-1- BARF1-4	2	9	30	56
Average for GES-1/ BARF1	4.5	12.0	33.5	58.0
TPA-GES-1-BARF1-1	7	19	48	99
TPA-GES-1-BARF1-2	6	17	43	97
TPA-GES-1-BARF1-3	5	13	39	93
TPA-GES-1-BARF1-4	6	15	42	95
Average for TPA-GES-1/BARF1	6.0	16.0	43.0	96.0

TPA: 12-O-tetradecanoylphorbol-13-acetate

Figure 5. Tumor formation in mice with SCID. The red arrow was the location of SCID mouse tumorigenic situation induced by TPA stimulation of cell groups expressing *BARF1* gene. SCID: severe combined immunodeficiency; TPA: 12-O-tetradecanoylphorbol-13-acetate. **Figure 6.** Tumor morphology.

whereas the normal control GES-1 and transfected with vector alone cell groups did not give any positive colonies, and the cells died.

Tumorigenicity of *BARF1*-Expressing Human Gastric Epithelial Cells in Mice with SCID

To determine whether *BARF1* expression contributes tumorigenicity to EBV-negative human gastric epithelial cells, all four cell groups, including GES-1-BARF1, TPA-GES-1-BARF1, GES-1, and GES-1-pcDNA3.1 (2×10^7 cells/mouse), were injected into mice with SCID (three mice with SCID for each cell group). An apparent mass formation could be palpated in mice with SCID mice with GES-1-BARF1 and TPA-GES-1-BARF1 cell groups after 5 days. However, the mice inoculated with GES-1-BARF1 cell group did not form tumors, and only a nodule was formed; the three mice inoculated with TPA-GES-1-BARF1 cell groups formed tumors eventually (Figure 5). The tumor size (cm) was approximately 1.8×2.0 (Figure 6), whereas those inoculated with GES-1 cells and GES-1-pcDNA3.1 cells were unable to induce any tumors in mice with SCID.

RNA was extracted from tumor tissues, and the expression of *BARF1* in tumor tissues was then detected by RT-

PCR. The results showed that *BARF1* gene was positive, indicating that *BARF1* gene expression was present in tumor tissues. The tumor tissues were stained with H&E and confirmed as adenocarcinoma (data not show); the tumor tissues were immunohistochemically stained (using serum of *BARF1*-positive patient with nasopharyngeal carcinoma as antibodies) in the cell membrane or cytoplasm, and the results showed that *BARF1* expression was positive (data not show).

DISCUSSION

EBV is a DNA oncogenic virus. Recently, great attention has been paid to the role that the EBV-encoded *BARF1* gene plays in gastric carcinogenesis. EBV-encoded *BARF1* is expressed in EBV-positive malignancies such as nasopharyngeal carcinoma, EBVaGCs, B-cell lymphoma, and nasal natural killer/T-cell lymphoma, and has been shown to have an important role in oncogenesis (24–27). In this study, a role for the EBV-encoded *BARF1* gene in GC occurrence and development was detected through the construction of human gastric epithelial cell lines carrying the *BARF1* gene.

The oncogenic properties of *BARF1* have been previously documented in other cell types (such as EBV-negative nasopharyngeal carcinoma cells, primate epithelial cells, rodent fibroblasts, HEK-293) forced to ectopically express *BARF1* (28–31). From our results, GES-1-*BARF1* cells became rounder, bigger, and more fusiform than GES-1 cells. The GES-1-*BARF1* cells were digested easily using trypsin. The adhesion of GES-1-*BARF1* cells was reduced, and they could grow in suspension medium. Both CCK-8 and colony formation assays inferred that *BARF1* might be a growth-promoting factor in the malignant transformation of gastric epithelial cells. However, mice with SCID could not form tumors with GES-1-*BARF1* cells. It is worth noting that the mice inoculated with TPA-GES-1-*BARF1* cell groups formed tumors eventually. These results show that tumor formation is a process of multi-stage and multi-factor interactions. Although the *BARF1* gene is an oncogene, it alone is insufficient to cause tumorigenesis. The tumorigenicity experiments were carried out using the oncogene *BARF1* as an initiator and using TPA as a cancer-promoting factor. Mice with SCID formed tumors through the interaction of oncogenes and tumor promoters.

Zur et al. (15) previously demonstrated that 9 of 10 cases were *BARF1* gene positive from 132 cases of EBV-positive gastric adenocarcinomas, which indicates that *BARF1* plays an important role in the malignant transformation

of gastric epithelial cells and in the maintenance of the malignant phenotype.

The migration and invasion of assays can be performed to assess the effects of *BARF1* on cell migration and invasion by transwell insert chambers: the expression of *BARF1* could be effectively enhance the ability of migration and invasion compared to the control, respectively, which indicate improve effects of *BARF1* on the migration and invasion of GC.

In conclusion, in this study, the cell cycle S phase was extended for GES-1-*BARF1* cells and TPA-GES-1-*BRAF1* cells. Malignant transformation was induced by *BARF1* gene transfection, which induced the characteristics of tumor cell growth in the *BARF1* gene-transfected cells. All of these findings suggest that the *BARF1* gene as an oncogene of EBV may play an important role in the malignant transformation of gastric epithelial cells.

Ethics Committee Approval: Ethics committee approval was received for this study from the Ethics Committee of North China University of Science and Technology.

Informed Consent: N/A.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – S.L., K.Z., Jintao L.; Design – S.L., K.Z., Jintao L.; Supervision – S.L., K.Z.; Resource – S.L.; Materials – K.Z., Jintao L.; Data Collection and/or Processing – F.Z., J.L., X.H., W.Z.; Analysis and/or Interpretation – S.L., K.Z., Jintao L.; Literature Search – F.Z., J.L., X.H., W.Z.; Writing – S.L., K.Z., Jintao L.; Critical Reviews – S.L., K.Z., Jintao L.

Acknowledgements: The authors would like to thank School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, China for their support and assistance in this study.

Conflict of Interest: The authors have no conflict of interest to declare.

Financial Disclosure: This study was supported by the Project of Science and Technology for overseas scholars in Hebei Province (No. CY201620), and the Project of North China University Science and Technology (No.28656002).

REFERENCES

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011; 61: 69-90. [Crossref]
2. Konturek PC, Konturek SJ, Brzozowski T. Gastric cancer and *Helicobacter pylori* infection. *J Physiol Pharmacol* 2006; 57: 51-65.
3. Jorge YC, Duarte MC, Silva AE. Gastric cancer is associated with NOS2 -954G/C polymorphism and environmental factors in a Brazilian population. *BMC Gastroenterol* 2010; 10: 64. [Crossref]

4. Chuang YS, Wu MC, Yu FJ, et al. Effects of alcohol consumption, cigarette smoking, and betel quid chewing on upper digestive diseases: a large cross-sectional study and meta-analysis. *Oncotarget* 2017; 8: 78011-22. [\[Crossref\]](#)
5. Campos F, Carrasquilla G, Koriyama C, et al. Risk factors of gastric cancer specific for tumor location and histology in Cali, Colombia. *World J Gastroenterol* 2006; 12: 5772-9. [\[Crossref\]](#)
6. Galván-Portillo MV, Cantoral A, Oñate-Ocaña LF, et al. Gastric cancer in relation to the intake of nutrients involved in one-carbon metabolism among MTHFR 677 TT carriers. *Eur J Nutr* 2009; 48: 269-76. [\[Crossref\]](#)
7. Aune D, De Stefani E, Ronco A, et al. Meat consumption and cancer risk: a case-control study in Uruguay. *Asian Pac J Cancer Prev* 2009; 10: 429-36
8. Burke AP, Yen TSB, Shekitka KM, Sobin LH. Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. *Mod Pathol* 1990; 3: 377-80.
9. McLaughlin-Drubin ME, Munger K. Viruses associated with human cancer. *Biochim Biophys Acta* 2008; 1782: 127-50. [\[Crossref\]](#)
10. Jha HC, Pei Y, Robertson ES. Epstein-Barr Virus: Diseases Linked to Infection and Transformation. *Front Microbiol* 2016; 7: 1602. [\[Crossref\]](#)
11. Akiba S, Koriyama C, Herrera-Goepfert R, Eizuru Y. Epstein-Barr virus associated gastric carcinoma: epidemiological and clinicopathological features. *Cancer Sci* 2008; 99: 195-201. [\[Crossref\]](#)
12. Iizasa H, Nanbo A, Nishikawa J, Jinushi M, Yoshiyama H. Epstein-Barr Virus (EBV)-associated Gastric Carcinoma. *Viruses* 2012; 4: 3420-39. [\[Crossref\]](#)
13. Nishikawa J, Yoshiyama H, Iizasa H, et al. Epstein-Barr Virus in Gastric Carcinoma. *Cancers (Basel)* 2014; 6: 2259-74. [\[Crossref\]](#)
14. Strockbine LD, Cohen JL, Farrah T, et al. The Epstein-Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor. *J Virol* 1998; 72: 4015-21. [\[Crossref\]](#)
15. zur Hausen A, Brink AA, Craanen ME, Middeldorp JM, Meijer CJ, van den Brule AJ. Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. *Cancer Res* 2000; 60: 2745-8. [\[Crossref\]](#)
16. Martorelli D, Houali K, Caggiari L, et al. Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: Bases for improved immunotherapy. *Int J Cancer* 2008; 23: 1100-7. [\[Crossref\]](#)
17. Hoebe EK, Hutajulu SH, van Beek J, et al. Purified hexameric Epstein-Barr virus-encoded BARF1 protein for measuring anti-BARF1 antibody responses in nasopharyngeal carcinoma patients. *Clin Vaccine Immunol* 2011; 18: 298-304. [\[Crossref\]](#)
18. Wynne A, Kanwar RK, Khanna R, Kanwar JR. Recent Advances on the Possible Neuroprotective Activities of Epstein-Barr Virus Oncogene BARF1 Protein in Chronic Inflammatory Disorders of Central Nervous System. *Curr Neuropharmacol* 2010; 8: 268-75. [\[Crossref\]](#)
19. Seto E, Yang L, Middeldorp J, et al. Epstein Barr virus (EBV) encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression. *J Med Virol* 2005; 76: 82-8. [\[Crossref\]](#)
20. Decaussin G, Sbih-Lammali F, de Turenne-Tessier M, Bouguermouh A, Ooka T. Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. *Cancer Res* 2000; 60: 5584-8.
21. Hayes DP, Brink AA, Vervoort MB, Middeldorp JM, Meijer CJ, van den Brule AJ. Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases. *Mol Pathol* 1999; 52: 97-103. [\[Crossref\]](#)
22. Seto E, Yang L, Middeldorp J, et al. Epstein-Barr virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression. *J Med Virol* 2005; 76: 82-8. [\[Crossref\]](#)
23. Hoebe EK, Le Large TY, Greijer AE, Middeldorp JM. BamHI-A rightward frame 1, an Epstein-Barr virus-encoded oncogene and immune modulator. *Rev Med Virol* 2013; 23: 367-83. [\[Crossref\]](#)
24. Mohidin TB, Ng CC. BARF1 gene silencing triggers caspase-dependent mitochondrial apoptosis in Epstein-Barr virus-positive malignant cells. *J Biosci* 2015; 40: 41-51. [\[Crossref\]](#)
25. Chang MS, Kim DH, Roh JK, et al. Epstein-Barr virus-encoded BARF1 promotes proliferation of gastric carcinoma cells through regulation of NF- κ B. *J Virol* 2013; 87: 10515-23. [\[Crossref\]](#)
26. Wang Y, Wang XF, Sun ZF, Luo B. Unique variations of Epstein-Barr virus-encoded BARF1 gene in nasopharyngeal carcinoma biopsies. *Virus Res* 2012; 166: 23-30. [\[Crossref\]](#)
27. Jang BG, Jung EJ, Kim WH. Expression of BamHI-A Rightward Transcripts in Epstein-Barr Virus-Associated Gastric Cancers. *Cancer Res Treat* 2011; 43: 250-4. [\[Crossref\]](#)
28. Sheng W, Decaussin G, Sumner S, Ooka T. N-terminal domain of BARF1 gene encoded by Epstein-Barr virus is essential for malignant transformation of rodent fibroblasts and activation of BCL-2. *Oncogene* 2001; 20: 1176-85. [\[Crossref\]](#)
29. Sall A, Caserta S, Jolicoeur P, Franqueville L, de Turenne-Tessier M, Ooka T. Mitogenic activity of Epstein-Barr virus-encoded BARF1 protein. *Oncogene* 2004; 23: 4938-44. [\[Crossref\]](#)
30. de Turenne-Tessier M, Jolicoeur P, Middeldorp JM, Ooka T. Expression and analysis of the Epstein-Barr virus BARF1-encoded protein from a tetracycline-regulatable adenovirus system. *Virus Res* 2005; 109: 9-18. [\[Crossref\]](#)
31. Jiang R, Cabras G, Sheng W, Zeng Y, Ooka T. Synergism of BARF1 with Ras induces malignant transformation in primary primate epithelial cells and human nasopharyngeal epithelial cells. *Neoplasia* 2009; 11: 964-73. [\[Crossref\]](#)